JPWO2021237068A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021237068A5 JPWO2021237068A5 JP2022570441A JP2022570441A JPWO2021237068A5 JP WO2021237068 A5 JPWO2021237068 A5 JP WO2021237068A5 JP 2022570441 A JP2022570441 A JP 2022570441A JP 2022570441 A JP2022570441 A JP 2022570441A JP WO2021237068 A5 JPWO2021237068 A5 JP WO2021237068A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- tcr
- variable region
- chain variable
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 32
- 239000002773 nucleotide Substances 0.000 claims description 32
- 125000003729 nucleotide group Chemical group 0.000 claims description 32
- 210000004027 cell Anatomy 0.000 claims description 31
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 28
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 24
- 210000002865 immune cell Anatomy 0.000 claims description 17
- 108091008874 T cell receptors Proteins 0.000 claims description 14
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 14
- 239000013604 expression vector Substances 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 210000004698 lymphocyte Anatomy 0.000 claims description 5
- 102000011786 HLA-A Antigens Human genes 0.000 claims description 4
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 230000000735 allogeneic effect Effects 0.000 claims description 4
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 4
- 210000000822 natural killer cell Anatomy 0.000 claims description 4
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 210000003289 regulatory T cell Anatomy 0.000 claims description 3
- 239000013603 viral vector Substances 0.000 claims description 3
- 108700028369 Alleles Proteins 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- 239000000232 Lipid Bilayer Substances 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 238000011394 anticancer treatment Methods 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 238000001815 biotherapy Methods 0.000 claims description 2
- 238000010370 cell cloning Methods 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 229960000390 fludarabine Drugs 0.000 claims description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 238000009169 immunotherapy Methods 0.000 claims description 2
- 230000002637 immunotoxin Effects 0.000 claims description 2
- 229940051026 immunotoxin Drugs 0.000 claims description 2
- 239000002596 immunotoxin Substances 0.000 claims description 2
- 231100000608 immunotoxin Toxicity 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 230000010412 perfusion Effects 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 230000001177 retroviral effect Effects 0.000 claims description 2
- 238000013207 serial dilution Methods 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 230000002463 transducing effect Effects 0.000 claims description 2
- 230000026683 transduction Effects 0.000 claims description 2
- 238000010361 transduction Methods 0.000 claims description 2
- 238000011282 treatment Methods 0.000 claims description 2
- 210000003954 umbilical cord Anatomy 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063028262P | 2020-05-21 | 2020-05-21 | |
| US63/028,262 | 2020-05-21 | ||
| PCT/US2021/033619 WO2021237068A2 (en) | 2020-05-21 | 2021-05-21 | T cell receptors with vgll1 specificity and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023526416A JP2023526416A (ja) | 2023-06-21 |
| JP2023526416A5 JP2023526416A5 (https=) | 2024-05-23 |
| JPWO2021237068A5 true JPWO2021237068A5 (https=) | 2024-05-23 |
Family
ID=76444666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022570441A Pending JP2023526416A (ja) | 2020-05-21 | 2021-05-21 | Ｖｇｌｌ１特異性を有するｔ細胞受容体およびその使用法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12552851B2 (https=) |
| EP (1) | EP4153301A2 (https=) |
| JP (1) | JP2023526416A (https=) |
| CN (1) | CN115803084A (https=) |
| AU (1) | AU2021275239A1 (https=) |
| CA (1) | CA3178726A1 (https=) |
| TW (1) | TW202208418A (https=) |
| WO (1) | WO2021237068A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024163292A1 (en) * | 2023-01-30 | 2024-08-08 | Board Of Regents, The University Of Texas System | T-cell receptors targeting her2 and methods of use thereof |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3964482A (en) | 1971-05-17 | 1976-06-22 | Alza Corporation | Drug delivery device |
| BE795384A (fr) | 1972-02-14 | 1973-08-13 | Ici Ltd | Pansements |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
| US4870287A (en) | 1988-03-03 | 1989-09-26 | Loma Linda University Medical Center | Multi-station proton beam therapy system |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| US5252334A (en) | 1989-09-08 | 1993-10-12 | Cygnus Therapeutic Systems | Solid matrix system for transdermal drug delivery |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| AU7326594A (en) | 1993-07-09 | 1995-02-06 | Synergen, Inc. | Recombinant ctla4 polypeptides and methods for making the same |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5697899A (en) | 1995-02-07 | 1997-12-16 | Gensia | Feedback controlled drug delivery system |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| US5656016A (en) | 1996-03-18 | 1997-08-12 | Abbott Laboratories | Sonophoretic drug delivery system |
| WO1997034634A1 (en) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
| US5760395A (en) | 1996-04-18 | 1998-06-02 | Universities Research Assoc., Inc. | Method and apparatus for laser-controlled proton beam radiology |
| US5739169A (en) | 1996-05-31 | 1998-04-14 | Procept, Incorporated | Aromatic compounds for inhibiting immune response |
| US5797898A (en) | 1996-07-02 | 1998-08-25 | Massachusetts Institute Of Technology | Microchip drug delivery devices |
| US5844905A (en) | 1996-07-09 | 1998-12-01 | International Business Machines Corporation | Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange |
| US5783208A (en) | 1996-07-19 | 1998-07-21 | Theratech, Inc. | Transdermal drug delivery matrix for coadministering estradiol and another steroid |
| US5779708A (en) | 1996-08-15 | 1998-07-14 | Cyberdent, Inc. | Intraosseous drug delivery device and method |
| JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド | 免疫療法のｃｔｌａ−４結合ペプチド |
| JP2002524081A (ja) | 1998-09-04 | 2002-08-06 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | 前立腺−特異的膜抗原に特異的な融合受容体およびその使用 |
| WO2000023573A2 (en) | 1998-10-20 | 2000-04-27 | City Of Hope | Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies |
| DK1141028T3 (da) | 1998-12-23 | 2010-05-25 | Pfizer | Humane monoklonale antistoffer til CTLA-4 |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| US20020131960A1 (en) | 2000-06-02 | 2002-09-19 | Michel Sadelain | Artificial antigen presenting cells and methods of use thereof |
| AU2001297703B2 (en) | 2000-11-07 | 2006-10-19 | City Of Hope | CD19-specific redirected immune cells |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US20040076955A1 (en) | 2001-07-03 | 2004-04-22 | Eos Biotechnology, Inc. | Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer |
| GB0203420D0 (en) | 2002-02-13 | 2002-04-03 | Oxford Biomedica Ltd | Peptide |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| US8353861B2 (en) | 2003-09-18 | 2013-01-15 | Texmac, Inc. | Applicator for applying functional substances into human skin |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| EP2520935A3 (en) | 2006-08-09 | 2013-02-13 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
| CA2682527C (en) | 2007-03-30 | 2017-07-11 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
| WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| TWI469791B (zh) | 2009-02-18 | 2015-01-21 | Oncotherapy Science Inc | Ｆｏｘｍ１胜肽以及含此胜肽之疫苗 |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| PL3053932T3 (pl) | 2010-02-19 | 2021-03-08 | Xencor, Inc. | Nowe immunoadhezyny CTLA4-IG |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CN110200997A (zh) | 2011-03-23 | 2019-09-06 | 弗雷德哈钦森癌症研究中心 | 用于细胞免疫治疗的方法和组合物 |
| US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
| KR102134932B1 (ko) | 2011-11-11 | 2020-07-17 | 프레드 헛친슨 켄서 리서치 센터 | 암을 위한 사이클린 ａ１―표적화된 ｔ―세포 면역요법 |
| JP6850528B2 (ja) | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| SG10201609210SA (en) | 2012-05-03 | 2016-12-29 | Hutchinson Fred Cancer Res | Enhanced affinity t cell receptors and methods for making the same |
| JP2014022858A (ja) | 2012-07-17 | 2014-02-03 | Murata Mfg Co Ltd | 電力増幅器 |
| CA2881981A1 (en) | 2012-08-20 | 2014-02-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| EP3718556A3 (en) | 2012-08-31 | 2020-12-30 | University Of Virginia Patent Foundation | Target peptides for immunotherapy and diagnostics |
| AU2013327136A1 (en) | 2012-10-02 | 2015-04-16 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| CA2917858A1 (en) | 2013-08-02 | 2015-02-05 | Aduro Biotech Holdings, Europe B.V. | Combining cd27 agonists and immune checkpoint inhibition for immune stimulation |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| KR101714649B1 (ko) | 2013-10-30 | 2017-03-10 | 한국생명공학연구원 | 암 치료 또는 암 전이 타겟으로서 vgll1의 용도 |
| WO2018067869A1 (en) | 2016-10-07 | 2018-04-12 | Board Of Regents, The University Of Texas System | Hla-restricted vgll1 peptides and use thereof |
-
2021
- 2021-05-21 AU AU2021275239A patent/AU2021275239A1/en not_active Abandoned
- 2021-05-21 US US17/999,496 patent/US12552851B2/en active Active
- 2021-05-21 WO PCT/US2021/033619 patent/WO2021237068A2/en not_active Ceased
- 2021-05-21 JP JP2022570441A patent/JP2023526416A/ja active Pending
- 2021-05-21 CA CA3178726A patent/CA3178726A1/en active Pending
- 2021-05-21 TW TW110118560A patent/TW202208418A/zh unknown
- 2021-05-21 EP EP21732751.9A patent/EP4153301A2/en not_active Withdrawn
- 2021-05-21 CN CN202180045414.4A patent/CN115803084A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7755890B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| ES2692206T3 (es) | Inmunoterapia combinada de receptores de reconocimiento de antígenos y células hematopoyéticas para el tratamiento de enfermedades | |
| ES2959480T3 (es) | Acoplador de células T - antígeno trifuncional y métodos y usos del mismo | |
| JP6336684B2 (ja) | Ｐｄ−ｌ１によって誘導される免疫寛容の低減 | |
| JP2021521776A5 (https=) | ||
| US11970545B2 (en) | T cell-antigen coupler with Y182T mutation and methods of uses thereof | |
| JPWO2019204683A5 (https=) | ||
| WO2019238722A1 (en) | Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders | |
| JP2017523784A5 (https=) | ||
| JP2018507685A (ja) | 治療免疫細胞の有効性を改良するための方法 | |
| US20180223255A1 (en) | Activation and Expansion of T Cells | |
| US20230277670A1 (en) | Chimeric molecules providing targeted costimulation for adoptive cell therapy | |
| EP3870146A1 (en) | Increase or maintaining t-cell subpopulations in adoptive t-cell therapy | |
| Zhang et al. | Genetic engineering with T cell receptors | |
| Petrausch et al. | Chimeric Antigen Receptors–“CARs” | |
| JP2021525067A5 (https=) | ||
| Savoldo et al. | Chimeric antigen receptors (CARs) from bench-to-bedside | |
| Zhang et al. | Strategies to improve the clinical performance of chimeric antigen receptor-modified T cells for cancer | |
| JP2022502078A5 (https=) | ||
| CN111499766B (zh) | 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用 | |
| JPWO2021237068A5 (https=) | ||
| US20240269182A1 (en) | Modified Chimeric Antigen Receptor and Use thereof | |
| JPWO2020185796A5 (https=) | ||
| WO2026082164A1 (en) | A modified dual-targeting t cell receptor complex and its pharmaceutical application thereof | |
| JPWO2019226946A5 (https=) |